Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

Gene-Sequencing Company Illumina to Sell Cancer Test Developer

The move came two days after a court upheld the Federal Trade Commission’s challenge to the deal on antitrust grounds.

Nicole Sperling
Author: Nicole Sperling

Written by

Nicole Sperling

in

Antitrust Laws and Competition Issues, Decisions and Verdicts, European Union, Federal Trade Commission, Genetic Engineering, Grail Inc, Illumina Inc, Mergers, Acquisitions and Divestitures, Regulation and Deregulation of Industry, Tests (Medical)
←Florida Republican Party Suspends Chairman, Demands Resignation Amid Rape Investigation
Trump Says Nevada Fake Electors Treated ‘Unfairly’ During Rally In Reno→

More posts

  • Rep. Jeff Van Drew’s Ex-Staffer Indicted After Allegedly Faking Anti-Trump Attack

  • ’90 Day Fiancé’ Star Sheila Mangubat Dead at 35

  • COP31 climate talks break down after angry dispute over fossil fuels

  • 5-Year-Old Boy Shot In The Head After Gun Was Left Unsecured in His Family’s Home

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube